Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels
NCT ID: NCT05184998
Last Updated: 2023-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
6950 participants
OBSERVATIONAL
2021-11-30
2022-07-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
At present, there are few studies to describe the clinical outcomes of HF patients with different sK levels in China. Utilizing the CN-HF database, this study is aimed to describe the sK levels of hospitalized HF patients and its impact to the clinical outcomes of patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
China National Heart Failure Registry
NCT02079428
Study of China Heart Failure Registry to Investigate Characteristics of Patients in China
NCT02664818
Demographic and Clinical Characteristics, Treatment Patterns and Clinical Outcomes of Heart Failure Patients in China
NCT03931200
Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China
NCT06099028
Cohort Study of Heart Failure With Preserved Ejection Fraction in Chinese Han
NCT05278026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Current guidelines in China recommend ACEi/ARBs, β receptor blockers, MRAs, and diuretics for treating HF patients . However, β receptor blockers, ACEi/ARB and MRA can also cause hyperkalemia , which often leads to dose reduction or even discontinuation of the medicines, it affects the patients to benefit from these treatment.
At present, there are few studies to describe the clinical outcomes of HF patients with different sK levels in China. Utilizing the CN-HF database, this study is aimed to describe the sK levels of hospitalized HF patients and its impact to the clinical outcomes of patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hypokalemia group
defined as sK range (0, 3.5\] mmo/L
No interventions assigned to this group
Normokalemia group
defined as sK range (3.5, 5.0\] mmo/L
No interventions assigned to this group
Hyperkalemia group
defined as sK range (5.0, \~) mmo/L
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jinming Zhou, PhD
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D9484R00002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.